MannKind (NASDAQ: MNKD)
MannKind Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
MannKind Company Info
MannKind Corp. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic products and devices for those with endocrine and orphan lung diseases. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.
News & Analysis
Why MannKind Stock Soared 19% Higher on Tuesday
The biotech delivered quite an impressive earnings report.
Why Shares of MannKind Are Up Wednesday
The company released its first-quarter earnings report on Tuesday.
Why Shares of MannKind Corporation Climbed 10.4% on Monday
The company is coming off an FDA approval for its second marketed drug.
Why Shares of MannKind Corporation Are Falling This Morning
Investors are hyperventilating after a delay for its inhaled medicine.
Why MannKind Corporation Stock Is Popping Today
An analyst is excited about the company's prospects.
Here's Why MannKind Corporation Remained Stuck in Reverse and Lost 24% in February
MannKind's reverse stock split gave investors the blues.
Why MannKind Corporation Stock Is Sinking Today
The biopharma's reverse split isn't a hit with investors.
3 Stocks to Avoid in Biotech
Biotech stocks are known for their high growth, but they can also be toxic for your portfolio if you don't invest wisely.
Valuation
Earnings Transcripts
MannKind (MNKD) Q4 2024 Earnings Call Transcript
MNKD earnings call for the period ending December 31, 2024.
MannKind (MNKD) Q3 2024 Earnings Call Transcript
MNKD earnings call for the period ending September 30, 2024.
MannKind (MNKD) Q2 2024 Earnings Call Transcript
MNKD earnings call for the period ending June 30, 2024.
MannKind (MNKD) Q1 2024 Earnings Call Transcript
MNKD earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.